The Swiss stock exchange closed lower, with the SMI down 0.26% at 11,384.92 points, marking a 3% loss over the week and reducing year-to-date gains to just 2%. Investor uncertainty stems from the Federal Reserve's cautious approach to interest rate cuts and concerns over a potential U.S. government shutdown. Notable declines were seen in UBS, Partners Group, and various insurance companies, while Idorsia plummeted 50.35% due to delays in drug negotiations.
UBS has maintained a "Buy" rating for Gerresheimer, setting a target price of 132 euros. Analyst Olivier Calvet highlighted that data on Novo Nordisk's weight-loss drug CagriSema could significantly impact Gerresheimer, positioning it favorably against competitors like Ypsomed.
UBS has maintained a Buy recommendation for Gerresheimer, setting a price target of 132 euros. Analyst Olivier Calvet notes that data from the study on Novo Nordisk's weight-lowering drug CagriSema could significantly impact the company's stock, as Gerresheimer is a key supplier.
UBS has maintained a "Buy" rating for Gerresheimer, setting a target price of 132 euros. Analyst Olivier Calvet highlighted that data from Novo Nordisk's weight-loss drug CagriSema could significantly impact Gerresheimer, positioning it favorably against competitors like Ypsomed.
UBS has maintained its "Buy" rating for Gerresheimer, setting a target price of 132 euros. Analyst Olivier Calvet noted that study data on Novo Nordisk's weight-loss drug CagriSema could significantly impact Gerresheimer, positioning it favorably against competitors like Ypsomed.
UBS has maintained a 'Buy' rating for Gerresheimer, setting a target price of 132 euros. Analyst Olivier Calvet noted that data from Novo Nordisk's weight-lowering drug CagriSema could positively impact Gerresheimer, positioning it favorably compared to Ypsomed. Schott Pharma and Stevanto remain unaffected.
UBS has upgraded Gerresheimer to a 'Buy' rating with a target price of 132 euros. Analyst Olivier Calvet noted that data from Novo Nordisk's weight-lowering drug CagriSema could significantly impact Gerresheimer, positioning it favorably compared to competitors like Ypsomed.
Swiss small and mid-cap companies present intriguing opportunities for portfolio diversification, particularly in sectors like medtech, which has outpaced the Swiss economy with 6% growth over the past decade. While some sectors face challenges, such as food and automotive, others, especially those linked to artificial intelligence and pharmaceuticals, are thriving. Current valuations in this segment are below historical averages, indicating potential for growth despite a seemingly unfavorable environment.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
